# EDGAR Filing Document

**Accession Number:** 0001133416
**File Stem:** 0001133416-25-000044
**Filing Date:** 2025-11
**Character Count:** 7843
**Document Hash:** 51e4da6c54355f297e17691cfb5fef42
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001133416-25-000044.hdr.sgml**: 20251105

**ACCESSION NUMBER**: 0001133416-25-000044

**CONFORMED SUBMISSION TYPE**: 4

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20251103

**FILED AS OF DATE**: 20251105

**DATE AS OF CHANGE**: 20251105

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** LEWIS JOEL
- **CENTRAL INDEX KEY:** 0001725595

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** 4
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-31791
- **FILM NUMBER:** 251453917

**MAIL ADDRESS:**
- **STREET 1:** 12575 ULINE DRIVE
- **CITY:** PLEASANT PRAIRIE
- **STATE:** WI
- **ZIP:** 53158
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** GALECTIN THERAPEUTICS INC
- **CENTRAL INDEX KEY:** 0001133416
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 043562325
- **STATE OF INCORPORATION:** NV
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 4960 PEACHTREE INDUSTRIAL BOULEVARD
- **STREET 2:** SUITE 240
- **CITY:** NORCROSS
- **STATE:** GA
- **ZIP:** 30071
- **BUSINESS PHONE:** 678-620-3186

**MAIL ADDRESS:**
- **STREET 1:** 4960 PEACHTREE INDUSTRIAL BOULEVARD
- **STREET 2:** SUITE 240
- **CITY:** NORCROSS
- **STATE:** GA
- **ZIP:** 30071

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** PRO PHARMACEUTICALS INC
- **DATE OF NAME CHANGE:** 20010612

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 4

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

[x] Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>LEWIS JOEL<br><sub>(Last) (First) (Middle)</sub><br>C/O GALECTIN THERAPEUTICS INC.<br>4960 PEACHTREE INDUSTRIAL BLVD., STE 240<br><sub>(Street)</sub><br>NORCROSS, GA 30071<br><sub>(City) (State) (Zip)</sub> | **3. Date of Earliest Transaction (Month/Day/Year)**<br>2025-11-03 | **5. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[X] Director [ ] 10% Owner<br>[X] Officer (give title below) [ ] Other (specify below)<br>_President and CEO_ |
| **2. Issuer Name and Ticker or Trading Symbol**<br>GALECTIN THERAPEUTICS INC [ GALT ] | **4. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | 3. Transaction Code (V) | 3. Transaction Code (V) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 4. Securities Acquired (A) or Disposed of (D) | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| 1. Title of Security | 2. Transaction Date | 2A. Deemed Execution Date | Code | V | Amount | (A) or (D) | Price | 5. Amount of Securities Beneficially Owned | 6. Ownership Form | 7. Nature of Indirect Beneficial Ownership |
| Common Stock | 2025-11-03 |  | M<sup>(1)</sup> |  | 1300 | A | $2.39 | 833892 | D |  |
| Common Stock | 2025-11-03 |  | S<sup>(1)</sup> |  | 1300 | D | 6.01<sup>(2)</sup> | 832592 | D |  |
| Common Stock | 2025-11-04 |  | M<sup>(1)</sup> |  | 14420 | A | $2.39 | 847012 | D |  |
| Common Stock | 2025-11-04 |  | S<sup>(1)</sup> |  | 14420 | D | 6.07<sup>(5)</sup> | 832592 | D |  |
| Common Stock |  |  |  |  |  |  |  | 2000 | I | as USTA custodian for a minor child<sup>(4)</sup> |

---

## Table II - Derivative Securities

---

|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | 4. Transaction Code (V) | 4. Transaction Code (V) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) | 6. Date Exercisable and Expiration Date | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Underlying Securities | 7. Title and Amount of Underlying Securities | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | 2. Conversion or Exercise Price | 3. Transaction Date | 3A. Deemed Execution Date | Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 8. Price of Derivative Security | 9. Number of Derivative Securities Beneficially Owned | 10. Ownership Form | 11. Nature of Indirect Beneficial Ownership |
| Stock option (right to buy) | $2.39 | 2025-11-03 |  | M<sup>(1)</sup> |  |  | 1300 | 2018-12-14<sup>(3)</sup> | 2027-12-14 | Common Stock | 1300 | $0 | 38950 | D |  |
| Stock option (right to buy) | $2.39 | 2025-11-04 |  | M<sup>(1)</sup> |  |  | 14420 | 2018-12-14<sup>(3)</sup> | 2027-12-14 | Common Stock | 14420 | $0 | 24530 | D |  |

---

### Footnotes:

(1) The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on April 17, 2025, as disclosed in the Issuer?s Quarterly Report on Form 10-Q, filed with the
SEC on August 14, 2025.

(2) The shares were sold in multiple transactions at prices ranging from $6.00 to $6.01. This amount represents the weighted average sale price of such transactions. The reporting personundertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder ofthe Issuer.

(3) The options vested 100% on December 14, 2018.

(4) These shares are held of record by the Reporting Person as custodian for a minor child under the Uniform Transfer to Minors Act. The Reporting Person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purpose of Section 16 or for any other purpose.

(5) The shares were sold in multiple transactions at prices ranging from $6.00 to $6.20. This amount represents the weighted average sale price of such transactions. The reporting personundertakes to provide full information regarding the number of shares sold at each separate price upon request by the Securities and Exchange Commission, the Issuer, or a security holder ofthe Issuer.

**Signature:** Jack W. Callicutt, by power of attorney  
**Date:** 2025-11-05

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**